Citi Upgrades Raptor Pharmaceuticals (RPTP) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Raptor Pharma (RPTP) Gains on New PROCYSBI Patents and Orphan Drug Exclusivity Extension
January 25, 2016 10:22 AM ESTRaptor Pharma (NASDAQ: RPTP) is gaining sharply after the company announced this morning that a U.S. PROCYSBI patent, number 9,233,077, is now... More
Raptor Pharma (RPTP) Announces FDA Orange Book Listing of PROCYSBI Patent
January 25, 2016 7:09 AM ESTRaptor Pharmaceutical Corp. (Nasdaq: RPTP) announced that a U.S. PROCYSBI patent, number 9,233,077, is now listed in the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The patent, entitled Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same, covers the enteric coated micro-bead formulation of PROCYSBI as well as other related formulations. This... More
